Previous 10 | Next 10 |
2023-12-04 16:40:10 ET More on TEGNA Why TEGNA Is A Buy Even As A Standalone Company TEGNA enters into $325 million accelerated share repurchase agreement For further details see: Tegna CEO David Lougee discloses sale of 100,000 shares
2023-11-30 12:02:39 ET More on iShares Russell 2000 ETF: IWM: Santa Rally On Steroids (Rating Downgrade) The Week On Wall Street: Holiday Edition IWM: Why The Small Cap Bounce May Continue Top buy and top sell ideas in each sector – Oppenheimer ...
2023-11-20 06:30:00 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Screening for stocks with low price-to-earnings ratios is a great place to start when looking for value stocks, but your search for low P/E value stocks should not end there. That is, it...
2023-11-15 17:51:28 ET More on E.W. Scripps E.W. Scripps: Business And Balance Sheet Challenges Set To Persist The E.W. Scripps Company (SSP) Q3 2023 Earnings Call Transcript E.W. Scripps Non-GAAP EPS of -$0.15 beats by $0.15, revenue of $566.53M in-line E.W....
2023-11-09 08:31:28 ET More on TEGNA Why TEGNA Is A Buy Even As A Standalone Company TEGNA Q3 2023 Earnings Preview Seeking Alpha’s Quant Rating on TEGNA For further details see: TEGNA enters into $325 million accelerated share repurchase agreement
TEGNA has committed this year to nearly $800 million in share repurchases TEGNA Inc. (NYSE: TGNA) today announced that it has entered into an accelerated share repurchase agreement (“ASR”) with JPMorgan Chase Bank, National Association (“JPMorgan”). Und...
2023-11-07 12:05:31 ET TEGNA Inc. (TGNA) Q3 2023 Earnings Conference Call November 07, 2023 10:00 AM ET Company Participants Julie Heskett - Senior Vice President Financial Planning & Analysis & Head of Investor Relations Dave Lougee - President & Chief E...
Transgene continues to advance its innovative immunotherapy pipeline, with key clinical development catalysts expected in the next 12 months Financial visibility until the end of 2024 Regulatory News: Transgene (Euronext Paris: TNG), a biotech company that designs and develops v...
2023-11-07 08:17:07 ET More on TEGNA Why TEGNA Is A Buy Even As A Standalone Company TEGNA: Despite Mixed Results, The Stock Is Undervalued TEGNA Q3 2023 Earnings Preview Seeking Alpha’s Quant Rating on TEGNA Historical earnings data for TEGNA ...
Increases shareholder return of capital commitment to nearly $800 million this year through accelerated share repurchase (“ASR”) programs, settlement of merger termination fee, and incremental opportunistic repurchases in the open market Completes initial $300 million AS...
News, Short Squeeze, Breakout and More Instantly...
Strasbourg, France, and Lund, Sweden, July 22, 2024, 8:00 a.m. CET – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, and BioInvent International AB (“BioInvent”) (Nasdaq Stock...
Gray Media stations in Anchorage and Juneau will broadcast all locally available Seattle Kraken games, free over-the-air beginning with the 2024-2025 season TEGNA Inc. (NYSE: TGNA), the Seattle Kraken and Gray Media (NYSE: GTN) today announced that Gray’s KAUU in Anchorage and ...
NEW YORK, July 11, 2024 (GLOBE NEWSWIRE) -- Olaplex Holdings, Inc. (NASDAQ: OLPX) (“OLAPLEX” or “the Company”) today announced the appointment of two highly seasoned leaders to its executive team. Catherine Dunleavy will join OLAPLEX as Chief Operating Officer and Chie...